<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952103</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan-CUP-003</org_study_id>
    <nct_id>NCT04952103</nct_id>
  </id_info>
  <brief_title>Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China</brief_title>
  <official_title>Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, real world study.The objective is to observe the diagnosis and&#xD;
      first-line treatment of Chinese patients with cancer of unknown primary, and collect the&#xD;
      clinicopathological characteristics, treatment outcomes, survival and other data of the&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2021</start_date>
  <completion_date type="Anticipated">June 18, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 18, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cancer of Unknown Primary Site</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>The patient's treatment is determined by the physician in charge according to the patient's clinical situation and relevant guidelines, without additional intervention.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cancer of unknown primary (CUP) and are gonging to receive the first-line&#xD;
        therapy for CUP&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Had a diagnosis of cancer of unknown primary (CUP) after a standard evaluation .&#xD;
&#xD;
          -  Prepared to receive first-line therapy for CUP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who had previously received systemic therapy for CUP&#xD;
&#xD;
          -  Previous history of other cancers, except cervix cancer or basal cell carcinoma of the&#xD;
             skin that has been cured&#xD;
&#xD;
          -  The investigator considered that there were contraindications to treatment or were not&#xD;
             appropriate to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xin Liu</last_name>
    <phone>13761503356</phone>
    <email>jeanettexin@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cencer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiguo Luo, MD,PhD</last_name>
      <phone>862164175590</phone>
      <phone_ext>8908</phone_ext>
      <email>luozhiguo88@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhiguo Luo, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

